Transgenic expression of neurotrophic factors in the skeletal muscle has been found to protect mice from 22 neuromuscular disease, including spinal bulbar muscular atrophy (SBMA), triggering renewed interest in 23 neurotrophic factors as therapeutic agents for treating neuromuscular disease. Because SBMA is an androgen-24 dependent disease, and brain-derived neurotrophic factor (BDNF) mediates the effects of androgens on neuromus-25 cular systems, we asked whether BDNF expression is impaired in two different transgenic (Tg) mouse models of 26 SBMA, the so called "97Q" and "myogenic" SBMA models. The 97Q model globally overexpresses a full length 27 human AR with 97 glutamine repeats whereas the myogenic model of SBMA overexpresses a wild-type rat 28 androgen receptor (AR) only in the skeletal muscle fibers. Using quantitative PCR, we find that muscle BDNF 29 mRNA declines in an androgen-dependent manner in both models, paralleling changes in motor function, with 30 robust deficits (6-8 fold) in both fast and slow twitch muscles of impaired Tg males. Castration rescues or reverses 31 disease-related deficits in muscle BDNF mRNA in both models, paralleling its effect on motor function. Moreover, 32 when disease is acutely induced in Tg females, both motor function and muscle BDNF mRNA expression plummet, 33 with the deficit in muscle BDNF emerging before overt motor dysfunction. That androgen-dependent motor 34 dysfunction is tightly associated with a robust and early down-regulation of muscle BDNF mRNA suggests that 35 BDNF delivered to the muscle may have therapeutic value for SBMA. 36
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We performed a two-factor between subjects analysis of variance to We find that castration of asymptomatic 97Q males at the start of 299 puberty protects animals from impairments in BDNF mRNA expression 300 in the muscle, paralleling its effect on motor function, maintaining both 301 at Wt levels (Fig. 2) . These data show that the transgene alone does not 302 cause the deficit in muscle BDNF mRNA. We note that castration at 303 puberty had no effect on either muscle BDNF expression or motor func-304 tion in Wt males. We also find that after three weeks, castration of 305 chronically diseased adult myogenic males largely reverses both deficits 306 in motor function and BDNF mRNA (Fig. 3) , while having no effect on (Fig. 4A ), comparable to that seen 321 in chronically diseased myogenic males (Fig. 1B) . The effect of andro-322 gens on the expression of BDNF mRNA in the muscle again shows a 323 striking correlation with motor function; each is severely compromised 324 after five days of T treatment (Fig. 4B) . We also found that the level of and if so, whether the deficit emerged before overt motor function.
365
We find that changes in muscle BDNF mRNA parallel changes in 366 motor function in both male Tg models. In the acute female model, we 367 find that the deficit in muscle BDNF mRNA develops within 24 h of an-368 drogen exposure, emerging before overt motor dysfunction, supporting 369 the idea that BDNF may critically underlie the loss in motor function.
370
BDNF expression in the skeletal muscle has been shown to be con-371 trolled by factors other than disease, including circulating T levels and 372 muscle activity levels (i.e., exercise). Unexpectedly, we find no effect 
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There is also growing precedence linking both mutant and Wt alleles (Fig. 2) . These data make it 
445
To further probe the androgen dependence of the BDNF deficit, we 446 treated myogenic females with T. When adult asymptomatic myogenic Fig. 3 . Castration reverses deficits in both muscle BDNF mRNA expression and motor function of chronically diseased myogenic males. Deficits in muscle BDNF (A) and motor function (B) found in gonadally intact Tg males are largely reversed by castration, indicating that both defects are androgen-dependent. Note that we find comparable BDNF deficits in gonadally-intact Tg males as seen in the first experiment (Fig. 1B) and rearing ability (Fig. 4B) , comparable to the severity of deficits seen 451 in chronically impaired (gonadally intact) myogenic males (Fig. 3B ).
452
Notably, we also saw comparable deficits in BDNF mRNA. 24 h of T exposure, a full two days before motor dysfunction emerged.
462
We were surprised to see the full magnitude of the deficit, about an 463~8 fold deficit, in muscle BDNF mRNA at the one day mark. These data To understand whether BDNF signaling per se might be altered,
468
we also examined the expression of BDNF receptors, the high- 1998; Stoop and Poo, 1996) . We previously showed that axonal trans- 
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Interestingly, our models show the same fragmentation of the junction by mobilizing the satellite cell population in the muscle.
531 Fig. 5 . Androgen induces the deficit in muscle BDNF mRNA before detectable motor dysfunction in acutely diseased myogenic females. Muscle BDNF mRNA was significantly reduced after only one day of testosterone (T) treatment (A). Importantly, this deficit preceded the loss in overt motor function; deficits in hang time were evident starting at three days of T treatment but not before. The magnitude of the deficit at 24 h was not only comparable to that at 5 days of T treatment in Tg females but also comparable to that of chronically affected myogenic and 97Q Tg males (Fig. 1) , suggesting that a defect in BDNF mRNA expression in the muscle is an early event in disease progression and might trigger the loss in overt motor function. 
